ARB (n = 578) | ACE-I (n = 1111) | p | |
---|---|---|---|
Baseline demographics | |||
Follow-up time (years) | 2.28 (1.48) | 2.27 (1.51) | 0.904 |
Age (years) | 77.2 (8.1) | 76.8 (8.6) | 0.377 |
Female (%) | 360 (62.3%) | 533 (48.0%) | < 0.001 |
Race (Caucasian) | 468 (81.0%) | 925 (83.3%) | 0.240 |
BMI (kg/m2) | 27.5 (5.0) | 27.1 (5.0) | 0.128 |
Education (years) | 14.3 (3.5) | 14.2 (3.6) | 0.577 |
Smoking history (years) | 11.4 (16.6) | 10.6 (16.4) | 0.342 |
Systolic BP (mmHg) | 139.0 (20.2) | 137.8 (20.4) | 0.269 |
Diastolic BP (mmHg) | 75.6 (11.2) | 74.3 (11.0) | 0.019 |
AD-related measures | |||
MMSE | 22.5 (4.9) | 21.8 (5.4) | 0.004 |
APOE ε4 carrier | 311 (53.8%) | 648 (58.3%) | 0.075 |
AD medication use | 396 (68.5%) | 738 (66.4%) | 0.387 |
Comorbidities | |||
Hypercholesterolemia | 376 (65.1%) | 727 (65.6%) | 0.818 |
Hypertension | 549 (95.0%) | 1025 (92.3%) | 0.112 |
Stroke/TIA history | 87 (15.1%) | 148 (13.3%) | 0.330 |
Heart failure | 29 (5.0%) | 43 (3.9%) | 0.268 |
Myocardial infarct | 43 (7.5%) | 120 (10.8%) | 0.026 |
Diabetes | 131 (22.7%) | 264 (23.8%) | 0.613 |
Depression | 246 (42.6%) | 408 (36.7%) | 0.019 |
Other medication use | |||
β-Blockers | 140 (24.2%) | 308 (27.7%) | 0.122 |
CCBs | 166 (28.7%) | 267 (24.0%) | 0.036 |
DRTCs | 220 (38.1%) | 370 (33.3%) | 0.052 |
Statins | 338 (58.5%) | 694 (62.5%) | 0.111 |
Antidepressants | 216 (37.4%) | 407 (36.6%) | 0.766 |
NSAIDs | 262 (45.3%) | 508 (45.7%) | 0.877 |